NEW ZEALAND

Did you know there are medical testing options available that could possibly help you target your cancer treatment?

Discover how FoundationOne Genomic Profiling can inform your unique cancer treatment plan.

Cancer treatment has evolved to become as unique as your cancer. Now we have medicines that target unique genomic alterations driving your cancer - so we need to find out which targeted treatment is right for you.

Comprehensive Genomic Profiling allows us to look for all types of known genomic alterations* across all of the cancer-related genes in a single sample of tumour tissue.

Find out how 
FoundationOne
may be able to
help you

Download the fact sheet

DOWNLOAD NOW

*All types of genomic alterations: Base substitutions, copy number alterations, rearrangements, insertions and deletions, as well as tumour mutational burden (TMB) and microsatellite instability (MSI) status.

Learn more about cancer and available treatment options.

Cancer explained in 3 minutes.

How can FoundationOne Comprehensive Genomic Profiling help you? 

FoundationOne may help to identify whether you could potentially benefit from targeted treatment.

Since there are hundreds of cancer genes, and many possible alterations in each gene, the type, number and combination of genomic alterations make each person’s cancer unique.

Comprehensive Genomic Profiling can search for all genomic alterations that are known to drive cancer, some of which may be promoting your tumour’s growth.

Your profiling results may help your doctor identify whether a targeted treatment option is available for your tumour’s unique genomic profile, and which treatment approach could yield the best outcome for you.

DOWNLOAD THE FACT SHEET

The process involved for FoundationOne Genomic Profiling

If you and your doctor decide that FoundationOne® Companion Diagnostic (CDx), FoundationOne® Liquid or FoundationOne® Heme test is right for you, your doctor will order the appropriate profile, and send a sample of your tumour or your blood to be analysed.

STEPS

Your doctor orders the profile.

The laboratory receives your tumour sample or blood sample.

DNA is extracted from your tumour or blood sample.

Unique genomic code of the tumour is identified.

A team of genomic experts analyses your unique data and matches your individual genomic alterations to potential targeted therapies or clinical trials.

Allow up to seven days for your local laboratory in New Zealand to source and prepare your sample for shipment. It typically takes 14 days from the time the tissue or blood sample is received in Boston, USA, for Foundation Medicine Inc to analyse and prepare your customised FoundationOne® CDx or FoundationOne® Liquid profile. FoundationOne® Heme takes approximately 21 days. After a total of approximately three to four weeks from the time your sample was taken your doctor will receive a detailed report containing information about your tumour’s genomic makeup and potential options for you and your doctor to consider.

Find out how FoundationOne®
may be able to 
help you

Download the fact sheet

DOWNLOAD NOW

Discuss FoundationOne with your Doctor 

Speak to your Oncologist about FoundationOne® and how it may be able to help you. Alternatively, contact one of the private treatment providers below to discuss your options.

Private Treatment Providers 

NORTHLAND

232 Wairau Road, Glenfield, Auckland 

Canopy Cancer Care

213 Shakespeare Road, Takapuna, Auckland

Canopy Cancer Care

98 Mountain Rd, Epsom, Auckland 

Auckland Oncology

125 Remuera Road, Remuera, Auckland 

AUCKLAND 

Harbour Cancer Centre

Canopy Cancer Care

121 Bank Street, Whangarei

www.canopycancercare.co.nzwww.canopycancercare.co.nzwww.canopycancercare.co.nzwww.harbourcancer.co.nzwww.aucklandoncology.co.nzwww.bowen.co.nz

Level B3, Bowen Specialist Medical Centre 
94 Churchill Drive, Crofton Downs, Wellington 

Southern Cross Hospital

WAIKATO
Braemar Cancer Care

Braemar Hospital, 24 Ohaupo Road, Hamilton

BAY OF PLENTY
Canopy Cancer Care

850 Cameron Rd, Tauranga 

CHRISTCHURCH
St Georges Cancer Care Centre

131 Leinster Road, Strowan, Christchurch 

58 Otonga Road, Rotorua 

DUNEDIN
Mercy Cancer Care

72 Newington Avenue, Maori Hill, Dunedin 

www.canopycancercare.co.nzwww.braemarhospital.co.nzwww.hospitals.southerncross.co.nzwww.stgeorgescancercarecentre.org.nzwww.mercycancercare.org.nz

Healthcare Professionals should visit www.foundationmedicine.co.nz for more information and to order a genomic profile for a patient.

About Foundation Medicine 

Foundation Medicine is a world-leading molecular insights company, connecting physicians and their patients to the latest cancer treatment approaches and making precision medicine a reality for thousands.

 In New Zealand, Roche’s pharmaceutical division is the licensed distributor of FoundationOne® CDx and FoundationOne® Liquid (for patients with solid tumours) and FoundationOne® Heme (for patients with haematological cancers or sarcomas), offering Comprehensive Genomic Profiling services and decision support tools that may inform cancer treatment decisions.

FoundationOne® CDx, FoundationOne® Liquid and FoundationOne® Heme Consumer Information Summary 

Description 
FoundationOne® CDx, FoundationOne® Liquid and FoundationOne® Heme are genomic tests that help you and your doctor understand the changes in your cancer’s genes which may be promoting your cancer’s growth. These tests are known as Comprehensive Genomic Profiles.  

  • FoundationOne® CDx and FoundationOne® Liquid are profiles used for solid tumours like lung cancer or skin cancer. 
  • FoundationOne®Heme is the profile used for blood and lymph cancers like leukaemias, lymphomas, and myelomas; and sarcomas. 
  • FoundationOne® profiles do not provide information about your inherited genetic alterations (passed down from generation to generation in families). 
  • Results may show one or more genomic alterations that are “actionable”. This means that there may be treatments available that target your specific type of cancer. There may also be clinical trials that are investigating therapies that target your specific type of cancer. However, it is also possible that the profiles will not reveal the cause of your disease or help identify possible treatments. 
  • These profiles do not explore every possible change or alteration that may exist and the technology may not identify all changes related to your individual cancer. 
  • There is a small possibility of errors. 
  • You may learn medical information about yourself that you did not expect, including learning of additional diagnoses or a change in your condition, which may or may not be treatable and may cause you distress. 
  • It is important for you to know that because genetic information is involved, it is possible that the results of your profile could impact your ability to obtain life, disability or long-term care insurance. 

Discover how FoundationOne Genomic Profiling can inform your unique cancer treatment plan. 

Cancer treatment has evolved to become as unique as your cancer. Now we have medicines that target unique genomic alterations driving your cancer - so we need to find out which targeted treatment is right for you.

Comprehensive Genomic Profiling allows us to look for all types of known genomic alterations* across all of the cancer-related genes in a single sample of tumour tissue.

*All types of genomic alterations: Base substitutions, copy number alterations, rearrangements, insertions and deletions, as well as tumour mutational burden (TMB) and microsatellite instability (MSI) status.

Did you know there are medical testing options available that could possibly help you target your cancer treatment?

Did you know there are medical testing options available that could possibly help you target your cancer treatment?

Use 
A sample of your tumour or blood is sent to the Foundation Medicine laboratory in the United States. After two to three weeks, your doctor will receive a report containing the profiling results for your tumour sample. The report contains a summary of possible targeted treatments, treatment approaches or available clinical trials. You and your doctor can then consider the treatment options that suit you best. 

Warnings and Precautions 
FoundationOne® CDx, FoundationOne® Liquid and FoundationOne® Heme profiling provide information about changes to your cancer genes. 

Speak to your oncologist about FoundationOne® CDx, FoundationOne® Liquid and FoundationOne® Heme and whether comprehensive genomic profiling may be able to help you. More information about Foundation Medicine comprehensive genomic profiles can be found at www.mycancerisunique.co.nz.

© © 2019 Foundation Medicine, Inc. Foundation Medicine® and FoundationOne® are registered trademarks. Roche is the licensed distributor of Foundation Medicine products outside of the United States. Roche Products (New Zealand) Ltd. Auckland. Customer Services team: 0800 880 177. 

PRIVACY STATEMENT | LEGAL STATEMENT

2019 Roche Products (New Zealand) Limited. Access to this site is subject to the terms in our Legal Statement. You accept these terms by continuing to access this site. This site was last updated September 2019. FM-NZ-0003/DA3EG/2019SEP 

WELLINGTON
Bowen Icon Cancer Centre

TIMELINES

Patient resources

Foundation Medicine information bookletFoundatonOne Liquid information bookletFoundation Medicine patient consent form